All In Biotech

Drug Trial Radar · NCT05593094

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Sep 3, 2020

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Conditions

  • Advanced Solid Tumors
  • HER2-positive Breast Cancer

Interventions

  • ZN-A-1041Drug

    ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD

  • ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1bDrug

    ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

  • ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1bDrug

    ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

  • ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1bDrug

    ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion

  • ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1cDrug

    ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

  • ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1cDrug

    ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

  • ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1cDrug

    ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 as a Monotherapy in Phase 1aTime frame: 23 days
  2. The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 in Combination with T-DM1 or with T-DXd, or in Combination with PHESGO or Herceptin plus PerjetaTime frame: 21 days
  3. RP2DTime frame: Through study completion, an average of 1 year

Locations

36 sites in 7 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa

    Tucson, Arizona

  • TOI Clinical Research

    Cerritos, California

  • UCSF Helen Diller Family CCC

    San Francisco, California

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Hospital

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Duke University School of Medicine

    Durham, North Carolina

  • MD Anderson Cancer Center

    Houston, Texas

  • Geelong Hospital

    Geelong, Victoria, Australia

  • Sunshine Hospital

    St Albans, Victoria, Australia

  • Centre Georges Francois Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut de Cancerologie de l Ouest

    Saint-Herblain, France

  • Gustave Roussy

    Villejuif, France

  • EDOG - Institut Claudius Regaud - PPDS

    Toulouse, Haute-Garonne, France

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS

    Parma, Emilia-Romagna, Italy

  • Asst Papa Giovanni XXIII

    Bergamo, Lombardy, Italy

  • Fondazione Policlinico Universitario A Gemelli-Rome

    Magnago, Lombardy, Italy

  • Auckland City Hospital

    Auckland, New Zealand

  • Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitario de Jaen

    Jaén, Spain

  • Hospital Beata Maria Ana

    Madrid, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Fundacion Instituto Valenciano de Oncologia (IVO)

    Valencia, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

    Argentona, Barcelona, Spain

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, LA Coruna, Spain

  • Hospital Universitario Ramon y Cajal

    A Gudiña, Orense, Spain

  • Hospital Universitario Virgen del Rocio

    Las Cabezas de San Juan, Sevilla, Spain

  • The Christie

    Manchester, Lancashire, United Kingdom

  • Clatterbridge Cancer Centre

    Liverpool, Merseyside, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.